About the Company
We do not have any company description for Taysha Gene Therapies, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Taysha Gene Therapies, Inc.
Taysha Gene Therapies Inc (TSHA) Q2 2025 Earnings Call Highlights: Regulatory Milestones and ...
Despite increased net loss, Taysha Gene Therapies Inc (TSHA) advances pivotal trials and strengthens financial position with ...
Taysha Gene Therapies, Inc.: Taysha Gene Therapies Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Commenced site activation for REVEAL pivotal trial in accordance with previously aligned upon key design elements, following receipt of No Objection Letter (NOL) from Health Canada and feedback from ...
Will Taysha Gene Therapies, Inc. (TSHA) Report Negative Q2 Earnings? What You Should Know
Taysha Gene Therapies, Inc. (TSHA) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus ...
Taysha Gene Therapies, Inc. (TSHA) Reports Q2 Loss, Beats Revenue Estimates
Taysha Gene Therapies, Inc. (TSHA) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.09 per share a year ago.
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Shares ... - ETF Daily News
Taysha Gene Therapies, Inc. has a 1 year low of $1.05 and a 1 year high of $4.32. The company has a market cap of $254.20 million, a P/E ratio of 1.97 and a beta of 0.96.
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $6.63 Consensus ...
Taysha Gene Therapies had a negative net margin of 229.67% and a negative return on equity of 106.36%. The firm had revenue of $2.02 million during the quarter, compared to analyst estimates of $2 ...
Taysha Gene Therapies Announces Proposed Public Offering of Common ...
DALLAS, May 28, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based ...
Taysha Gene Therapies to Release Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 12
Detailed price information for Taysha Gene Therapies Inc (TSHA-Q) from The Globe and Mail including charting and trades.
Taysha Gene Therapies, Inc. (TSHA) Reports Q1 Loss, Tops Revenue ...
Taysha Gene Therapies, Inc. (TSHA) came out with a quarterly loss of $0.08 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.10 per share a year ago.
Taysha Gene Therapies Announces Pricing of Public Offering of Common ...
DALLAS, May 28, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based ...
Similar Companies
Loading the latest forecasts...